Evodiamine Exerts an Anti-Hepatocellular Carcinoma Activity through a WWOX-Dependent Pathway

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Evodiamine, a key compound from *Evodia rutaecarpa*, exhibits anti-cancer properties.
• The exact mechanisms underlying evodiamine's anti-cancer effects, particularly its interaction with WWOX, are not fully understood.
• Previous research suggests evodiamine influences beta-catenin, and WWOX regulates beta-catenin accumulation.

Purpose of the Study:

• To investigate the effect of evodiamine on hepatocellular carcinoma (HCC) cell proliferation.
• To elucidate the role of WW domain-containing oxidoreductase (WWOX) in evodiamine's anti-cancer activity.
• To determine if evodiamine's anti-HCC effects are mediated through a WWOX-dependent pathway.

Main Methods:

• Cell proliferation assays using *Mus musculus* and *Homo sapiens* HCC cell lines (Hepa1-6, HepG2).
• In vivo therapeutic efficacy testing in Hepa1-6 hepatoma-bearing mice.
• Western blot analysis to assess WWOX expression levels.
• WWOX knockdown experiments in HCC cell lines.

Main Results:

• Evodiamine demonstrated dose- and time-dependent inhibition of HCC cell proliferation in vitro.
• Oral administration of evodiamine significantly reduced tumor size in a mouse model of HCC.
• Evodiamine treatment led to a dose-dependent increase in WWOX expression in HCC cells and tumors.
• Knockdown of WWOX attenuated the anti-proliferative effects of evodiamine.

Conclusions:

• Evodiamine exerts anti-HCC activity through a WWOX-dependent mechanism.
• Evodiamine activates WWOX to inhibit hepatocellular carcinoma growth.
• Evodiamine shows potential as a therapeutic or preventive agent for HCC.